Regencell Bioscience Holdings Ltd (RGC): Cash & Equivalents
Older than the company's other figures. The latest Cash & Equivalents is for the year ended 2022-06-30, while the company's latest annual report covers the year ended 2026-06-30. Its later filings do not report this line under the concept TickerFacts maps.
$6.42M
As of 2022-06-30
+197.7%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2022-06-30 | $6.42M | n/m | 2022-10-31, Balance as of period end |
| 2021-06-30 | $59.4K | -84.6% | 2022-10-31, Balance as of period end |
| 2020-06-30 | $387.0K | +59.0% | 2021-10-29, Balance as of period end |
| 2019-06-30 | $243.3K | n/a | 2021-10-29, Balance as of period end |